Mona Bafadhel

Goulstonian Lecturer -  Royal College of Physicians 2019 

Graham Bull Prize - Royal College of Physicians 2018

Professor Bafadhel receives prestigious Royal College of Physicians award

CLINICAL TRIALS

The STOIC Study - Treating COVID19 infection with inhaled steroids: ClinicalTrials.gov Identifier: NCT04416399

The ABRA Study - Acute exacerbations treated with Benralizumab: ClinicalTrials.gov Identifier: NCT04098718

The CORAL Study - Study of relationship between changes in inflammation. lung function, symptoms and medication use in COPD patients: ClinicalTrials.gov Identifier: NCT04168216

The STARR Study - Stratified treatment to reduce risk in COPD: ClinicalTrials.gov Identifier: NCT04458636

OBSERVATIONAL TRIALS

The AES Study - Investigation of immune mechanism of the airway epithelium

The HAMS Study - A prospective observational study using home monitoring devices for patients with asthma

The OPTIMAN Study - Using exhaled nitric oxide in asthma

DPHIL PROJECTS

'Developing predictive tools for chronic obstructive pulmonary disease' -  Mr Andreas Halner 

'Investigating the role of the eosinophil in chronic obstructive pulmonary disease' - Mr James Camp 

'The role of epithelial cells in the pathogenesis of chronic obstructive pulmonary disease' - Mr Rassin Lababidi 

'Exacerbations of asthma and chronic obstructive pulmonary disease: assessment, inflammation and treatments' - Dr Sanjay Ramakrishnan

GLOBAL COMMUNITY

CICERO: Chair of an Europe-wide collaboration looking to investigate endotypes in severe hospitalised exacerbations of COPD. 

Lancet COPD Commission: Lead of exacerbation sub-section of upcoming Lancet COPD commission, looking to redefine the exacerbation event for the respiratory community worldwide

I am an Associate Professor of Respiratory Medicine and Consultant Respiratory Physician. My main focus of work is in translational science in the field of chronic obstructive pulmonary disease (COPD), particularly in exacerbations of COPD. The group investigates the mechanisms and therapeutic strategies aligned to endotypes of COPD.

So far, by studying eosinophils in COPD, this work has shown that evaluation of eosinophils relates to frequency of exacerbations, response to treatment with inhaled steroids and led to drug discovery using monoclonal antibodies to prevent exacerbations of COPD. My work has influenced international guidelines, such that eosinophils are now measured routinely in clinical practice for treatment initiation and continuation. 

My group, consists of 1 postdoctoral scientist, 4 senior research nurses, 2 clinical fellows, 1 research assistant, 1 trials manager and 3 DPhil students. The group are currently investigating the following: 

1. Characterisation of patients with COPD, utilising near-patient point of care testing to deliver systemic corticosteroid treatment at the time of an exacerbation.
2. Using mathematical approaches to investigate biological, physiological and symptom changes in COPD
3. The epithelial cell response to infection, particularly non-typeable H.influenzae and immunity in COPD
4. Establishing the role of the eosinophil in the mechanism of COPD.
5. Developing monitoring devices and tools, with abilities to influence clinical change in asthma and COPD